Two-year results from the EUREkA cohort show sustained effectiveness of anti-CGRP monoclonal antibodies for migraine, with identifiable factors predicting long-term persistence.
Sustained at 24 monthsAnti-CGRP antibodies continued reducing headache days after 2 years of treatment
What the researchers found
Anti-CGRP monoclonal antibodies demonstrated sustained effectiveness at 24 months with significant reduction in monthly headache days, and baseline factors predicting 2-year treatment persistence were identified.
Why it matters
Long-term effectiveness data justifies continued insurance coverage and helps patients commit to treatment knowing it maintains efficacy over 2 years.
How the study worked
Prospective observational multicenter registry study (EUREkA cohort) analyzing anti-CGRP MAb effectiveness and persistence factors at 24 months.
What this study cannot tell us
Observational registry — no control group. Survivor bias may inflate effectiveness if non-responders dropped out early.
How to read the evidence
Prospective multicenter registry — strong real-world evidence for long-term effectiveness.
When this study was published
Published in 2026; provides mature long-term data on anti-CGRP therapies.
The bigger picture
This provides the long-term real-world evidence needed to establish anti-CGRP therapies as durable first-line migraine prevention treatments.
Questions still open
- Do benefits continue beyond 2 years?
- Which baseline factors most strongly predict long-term success?
Common questions
Do anti-CGRP migraine drugs keep working long-term?
How do I know if anti-CGRP therapy will work for me long-term?
Read the original research
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.
Neurology, 106(4), e214659
Citation
Caronna, Edoardo; Mas-de-Les-Valls, Rut; Egeo, Gabriella; Millán Vázquez, Manuel; Nieves-Castellanos, Candela; Portocarrero-Sánchez, Leonardo; Vaghi, Gloria; Rodríguez-Montolio, Joana; Jaimes, Alex; Muñoz-Vendrell, Albert; Oliveira, Renato; Polanco, Marcos; González Osorio, Yesica; Canales, Javiera; Ornello, Raffaele; Thunstedt, Cem; Fernández-Lázaro, Iris; Husøy, Andreas; Sánchez-Soblechero, Antonio; Nunes Vicente, Beatriz; Riesco, Nuria; Flores Pina, Belén; Fernandes, Catarina; Lopez, Alberto Andres; Martins-Silva, Elisa; Budrewicz, Sławomir; Gallardo, Víctor José; Gómez Dabó, Laura; Torres-Ferrus, Marta; Alpuente, Alicia; Torelli, Paola; Aurilia, Cinzia; Lamas, Raquel; Ruiz Castrillo, Maria José; De Icco, Roberto; Sances, Grazia; Broadhurst, Sarah; Winstanley, Jed; Gómez, Andrea; Campoy, Sergio; Marques, Inês; Parreira, Elsa; Gárate, Gabriel; Pascual, Julio; Guerrero Peral, Angel Luis; Caponnetto, Valeria; Straube, Andreas; Gonzalez-Martinez, Alicia; Quintas, Sonia; Sánchez-Del-Río, Margarita; Tronvik, Erling; Venegas Pérez, Begoña; Oterino Duran, Agustín; Rodrigues, Miguel; Cevoli, Sabina; Colombo, Bruno; Trimboli, Michele; Frediani, Fabio; d'Onofrio, Florindo; Aguggia, Marco; Salerno, Antonio; Carnevale, Antonio; Zucco, Maurizio; Albanese, Maria; Finocchi, Cinzia; Ranieri, Angelo; Zoroddu, Francesco; Autunno, Massimo; Sanahuja, Jordi; Waliszewska-Prosół, Marta; Pereira, Liliana; Layos-Romero, Almudena; Luzeiro, Isabel; Dorado, Laura; Alvarez-Escudero, Rocio; Martins, Isabel Pavao; Sundal, Christina; Irimia, Pablo; Lozano Ros, Alberto; Gago-Veiga, Ana Beatriz; Juanes, Fernando Velasco; Ruscheweyh, Ruth; Sacco, Simona; García-Azorín, David; González-Quintanilla, Vicente; Gil-Gouveia, Raquel Santos; Huerta Villanueva, Mariano; Rodríguez-Vico, Jaime; Lasaosa, Sonia Santos; Ghadri-Sani, Mona; Tassorelli, Cristina; Díaz De Terán Velasco, Francisco Javier; Diaz-Insa, Samuel; González Oria, Carmen; Barbanti, Piero; Pozo-Rosich, Patricia. (2026). Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.. Neurology, 106(4), e214659. https://doi.org/10.1212/WNL.0000000000214659